Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]
August 30, 2010
Tags: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Infectious disease, Scholars Program Posted in: Anthrax vaccines, Biosolutions, Business, El-Hibri Peace Education Prize, Emergent BioSolutions, Infectious disease, Scholars Program, fuad el-hibri 
No Comments
Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
August 3, 2010
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States., US government Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri No Comments
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]
July 15, 2010
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, US government Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri No Comments
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]
July 13, 2010
Tags: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, NATO, United States Department of Health and Human Services, United States. Posted in: Emergent BioSolutions, NATO, North Atlantic Treaty Organization, United States Department of Health and Human Services, Vaccine. No Comments
Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments
ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company’s international sales efforts have resulted in these sales [...]
July 7, 2010
Tags: Anthrax vaccines, BioSolutions Inc, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease Posted in: Anthrax vaccines, Biothrax, El-Hibri, Emergent BioSolutions, Vaccine., fuad el-hibri No Comments
Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]
May 18, 2010
Tags: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Research and development, Tech Council of Maryland Posted in: CEO, Department of Health and Human Services, Emergent BioSolutions, Research and development, Tech Council of Maryland, fuad el-hibri No Comments
Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]
December 17, 2009
Tags: Emergent BioSolutions, Ernst & Young, Federal government of the United States, Food and Drug Administration, Porton Product, United States. Posted in: Biosolutions, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, fuad el-hibri No Comments